Auxilium Health Lands $3.4M to Advance Biomaterial Platform Toward FDA Clearance

The company will use the funding to expand its operations and continue developing its products.

For decades, biomaterials have been designed to kill bacteria after they reach the surface of a medical device or implant. The goal has been to help healing cells grow before bacteria can cause an infection.

Read More:Brinc Raises $125M in Funding Round led by Motorola Solutions

Auxilium uses a different approach. Its Aer™ platform is designed to imitate the body's natural tissue structure, making it harder for bacteria to attach while encouraging healthy cells to grow. It does this without using antibiotics.

"Last year, the question was whether the science was real. This year, it's how fast we can get it to patients," said Isaiah Kaiser, PhD, Founder and CEO of Auxilium Health. "We are grateful to our investors and partners who believe in the science and the team behind what we're building. Their confidence lets us move with the urgency this problem deserves."

About Auxilium Health

Founded by Isaiah Kaiser, Auxilium Health is based at the Cleveland Clinic's Global Innovation Center. The company is supported by the National Science Foundation, the Ohio Department of Development and the Polymer Industry Cluster. Auxilium Health develops advanced bioaerogels that help prevent bacterial growth while supporting tissue healing. Its Aer platform is designed for wound care, bone regeneration and targeted drug delivery, with its lead product moving toward FDA clearance and clinical studies.

Read More:Sabanto Secures Series B to Grow Autonomous Tractor Technology